Deuterium in Living Organisms May Provide Clues to Prevent and Treat Cancer
Sub-molecular cellular events, driven by hydrogen’s replacements with deuterium, explain medical and economical failures of targeted molecular cancer drugs, which are the main conclusions of the 3 rd International Congress on Deuterium Depletion held in Budapest, Hungary, in May 2015. The Hungarian Nobel-prize winning scientist Albert Szent-Györgyi envisioned cancer cures that go beyond large molecules including genes and proteins, but rather target sub-molecular mechanisms, where the electrons play a role. Dr. Gábor Somlyai, Hungarian “sub-molecular” biologist, had begun investigations in 1990 regarding naturally occurring deuterium (D; heavy hydrogen (H)) as the cause of cancer. Results presented at the meeting clearly show that the D/H ratio in cellular water pools and the transfer of their deuterium content to different structural and functional molecules via reductive synthesis are essential for maintaining normal cellular functions, DNA and protein integrity. Pharmaceutical manufacturing of deuterium depleted nutritional products, including deuterium-depleted water, the proprietary procedure established by HYD LLC for Cancer Research & Drug Development, has broad potentials to enhance the effectiveness of current oncotherapies, as well as to innovate new ones.
The pharmaceutical industry has been seeking magic bullets to target specific genes and gene products, which continue to produce significant medical and economical challenges via drug failures, narrow range of responders, anecdotal cures claiming false evidence, poor quality of life from severe compound toxicities with enormous and unsustainable treatment costs. Gábor Somlyai PhD, Hungarian molecular biologist, was the first who recognized the biological importance of heavy hydrogen, i.e. deuterium, which can replace hydrogens due to its high concentrations in hydrogen bonding networks with undesired consequences that affect DNA stability in mammalian cells.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
